Contents
01 July 2020
Vol 12, Issue 550
Vol 12, Issue 550
Research Articles
- Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti–PD-1 antibody in patients with mesothelioma and mouse tumor models
Mesothelin-targeted immunotoxin LMB-100 with anti–PD-1 antibody enhanced antitumor activity in patients with mesothelioma and mouse tumor models.
- Circulating transcripts in maternal blood reflect a molecular signature of early-onset preeclampsia
Circulating transcripts reflect biologically relevant changes in early-onset severe preeclampsia and can accurately classify patient status.
- Intestinal goblet cells protect against GVHD after allogeneic stem cell transplantation via Lypd8
Goblet cells play a protective role against GVHD after allogeneic stem cell transplantation in a Lypd8-dependent manner.
- An ultrafast insulin formulation enabled by high-throughput screening of engineered polymeric excipients
Monomeric insulin stabilized with polymeric excipient exhibits increased stability and faster pharmacokinetics than current rapid-acting insulins.
Report
- Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits
Understanding antibody epitope diversity and affinity generated by SARS-CoV-2 spike antigens in rabbits can aid COVID-19 vaccine development.
Editors' Choice
- Cellular senolytics
Repurposing CAR T cells to target senescent cells ameliorates liver fibrosis and extends survival in mice with lung adenocarcinoma.
- Less is more for adoptive immunotherapy?
p38 inhibition augments adoptive T cell therapy by making T cells “fitter.”
- Nanosponges intercept coronavirus infection
Nanoparticles cloaked in human lung and immune cell membranes act as decoys to neutralize SARS-CoV-2 in cell culture, preventing host cell infection.
About The Cover
ONLINE COVER A One-Two Punch Against Mesothelioma. This image depicts immunohistochemical staining of mesothelioma, a rare but aggressive lung tumor with very limited therapeutic options. The marker stained in brown is mesothelin, a protein that is highly expressed in mesothelioma, but not in most normal adult tissues. Jiang et al. showed that mouse models and patients with mesothelioma become more sensitive to immune checkpoint blockade after treatment with an immunotoxin targeting mesothelin, resulting in greatly improved therapeutic outcomes. [CREDIT: MARKKU MIETTINEN/NATIONAL CANCER INSTITUTE]
